Log in to save to my catalogue

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_398a2dfd9ac6483f881f1a81f6f17840

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

About this item

Full title

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-08, Vol.15 (1), p.6894-13, Article 6894

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

SARS-CoV-2 has the capacity to evolve mutations that escape vaccine- and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the virus would thus be a valuable biomedical tool that would maintain its efficacy despite the ongoing emergence of...

Alternative Titles

Full title

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_398a2dfd9ac6483f881f1a81f6f17840

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_398a2dfd9ac6483f881f1a81f6f17840

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-51046-w

How to access this item